EMA Authorised: Rhokiinsa (netarsudil) — Santen Oy

View source ↗

Summary

The EMA authorised Rhokiinsa (netarsudil) by Santen Oy for open-angle glaucoma and ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Rhokiinsa (netarsudil)

Snippet

Status: Authorised. Therapeutic area: Glaucoma, Open-Angle;Ocular Hypertension. MAH: Santen Oy. Decision date: 09/10/2025